Affiliation:
1. Universidade de São Paulo Faculdade de Ciências Farmacêuticas de Ribeirão Preto
2. University of Sao Paulo: Universidade de Sao Paulo
3. Harvard Medical School
4. Boldrini Children Center
5. Boldrini
Abstract
Abstract
Groups (Grp) 3 and 4 are aggressive molecular subgroups of medulloblastoma (MB), with high rates of leptomeningeal dissemination. To date, there is still a paucity of biomarkers for these subtypes of MBs. In this study, we investigated the clinical significance and biological functions of Musashi-1 (MSI1) in Grp3 and Grp4-MBs. First, we assessed the expression profile of MSI1 in 59 primary MB samples (15-WNT, 18-SHH, 9-Grp3, 17-Grp4 subgroups) by qRT-PCR. MSI1 mRNA expression levels were also validated in an additional public dataset of MBs (GSE85217). The ROC curve was used to validate the diagnostic standards of MSI1 expression. Next, the potential correlated cell-cycle genes were measured by RNA-Seq. Cell cycle, cell viability, and apoptosis were evaluated in a Grp3/Grp4 MB cell line after knockdown of MSI1 and cisplatin treatment. We identified an overexpression of MSI1 with a high accuracy to discriminate Grp3/Grp4-MBs from non-Grp3/Grp4-MBs. We identified that MSI1 knockdown not only triggered transcriptional changes in the cell cycle pathway, but also affected G2/M phase in vitro, supporting the role of knockdown of MSI1 in cell cycle arrest. Lastly, MSI1 knockdown decreased cell viability and sensitized D283-Med cells to cisplatin treatment by enhancing cell apoptosis. Based on these findings, we suggest that MSI1 modulates cell cycle progression and may play a role as biomarker for Grp3/Grp4-MBs. In addition, MSI1 knockdown combined with cisplatin may offer a potential strategy to be further explored in Grp3/Grp4-MBs.
Publisher
Research Square Platform LLC
Reference39 articles.
1. Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values;Chagas PF;J Mol Neurosci,2022
2. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes;Sharma T;Acta Neuropathol,2019
3. Intertumoral Heterogeneity within Medulloblastoma Subgroups;Cavalli FMG;Cancer Cell,2017
4. Recent advances in the molecular understanding of medulloblastoma;Funakoshi Y;Cancer Sci,2023
5. Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD et al. Medulloblastoma. Nat Rev Dis Primers 2019, 5(1):11.